The latest biotech news

News and Trends 1 Sep 2022

Sanofi’s first treatment in the U.S. approved for adults and children with ASMD

A rare, inherited disease that affects the body’s ability to metabolize fat, cholesterol and lipids within cells can now be treated by Xenpozyme, a drug approved by the U.S. Food and Drug Administration (FDA). Adults and children with non-central nervous system (non-CNS) manifestations of acid sphingomyelinase deficiency (ASMD) can now take healthcare company Sanofi’s Xenpozyme […]

September 1, 2022 - 4 minutesmins - By Liza Laws

News and Trends 1 Sep 2022

Labiotech adds conference and event listings

In the past few months, Labiotech.eu has boosted its coverage range to go global, added a podcast, expanded to three weekly newsletters, introduced special monthly newsletters, and now we’ve added another string to our bow – conference and event listings. The page is designed so visitors can easily jump between months and events. Listings have […]

September 1, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 1 Sep 2022

Ensysce Biosciences and Quotient Sciences to develop opioid to prevent abuse and overdose

Ensysce Biosciences, Inc., a clinical-stage biotech company, and Quotient Sciences, a drug development and manufacturing accelerator, are partnering to support the development and clinical testing of PF614-MPAR. PF614-MPAR is a novel opioid combination product for the potential treatment of chronic pain that is designed to prevent both abuse and overdose. Quotient Sciences is currently using […]

September 1, 2022 - 2 minutesmins - By Jim Cornall

Futura medical erectile dysfunction medication

News and Trends 31 Aug 2022

Gel treatment for erectile dysfunction receives positive results from clinical trial

Futura Medical has announced positive results from a clinical trial looking into MED3000, a topical gel formulation for the treatment of erectile dysfunction (ED). The results, from the confirmatory phase 3 clinical study, FM71, were announced today (August 31). MED3000 is a breakthrough, fast-acting gel produced by Futura Medical’s transdermal DermaSys drug delivery technology. It […]

August 31, 2022 - 3 minutesmins - By Liza Laws

acute respiratory distress syndrome pantherna therpeutics inflammatory lung disease

News and Trends 31 Aug 2022

Regulatory approval given to Iceland’s EpiEndo for study of COPD treatment

A treatment for chronic respiratory disorders will be the subject of a clinical trial in Iceland after regulatory and ethics approval was granted. EpiEndo Pharmaceuticals will start a clinical trial of its lipopolysaccharide challenge with lead molecule EP395. Available orally, EP395 is an macrolide or Barriolide with reduced antimicrobial activity which aims to address the […]

August 31, 2022 - 2 minutesmins - By Liza Laws

News and Trends 31 Aug 2022

Anti-cancer drug created from reprogrammed yeast

Engineered yeast cells can synthetically produce the essential cancer medicine vinblastine, an international team of scientists showed in a new study published in Nature. In the summer and fall of 2019, some cancer patients experienced interruptions in their treatment. The reason was a shortage of the drugs vinblastine and vincristine, essential chemotherapeutic medicines for several […]

August 31, 2022 - 5 minutesmins - By Jim Cornall

News and Trends 31 Aug 2022

Researchers try to bridge gap in link for patients with salmonella infection and clogged arteries

Researchers from Taiwan have discovered that patients with non-typhoidal salmonella (NTS) have higher aortic calcification and elevated plasma levels, which are an inflammatory biomarker. They say their findings suggest the need for early diagnosis of the condition in patients with atherosclerosis risk factors. NTS is a foodborne bacterium causing gastrointestinal infections and can cause life-threatening […]

August 31, 2022 - 4 minutesmins - By Liza Laws

News and Trends 31 Aug 2022

Compound found in trees has potential to kill drug-resistant bacteria

Researchers say the naturally-occurring compound hydroquinine has bacterial killing activity against several microorganisms. Antimicrobial resistance has become one of the greatest threats to public health globally. It occurs when bacteria, viruses, fungi and parasites change over time and no longer respond to medicines, making it difficult to treat infections. Because of this, there is a […]

August 31, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 31 Aug 2022

Researchers identify possible target for type of sporadic ALS

Researchers have published two papers describing how they identified a potential new pathway for treating a sporadic form of amyotrophic lateral sclerosis (ALS). The studies were published as part of a cooperative research agreement between the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health, and the Swiss biotech […]

August 31, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 31 Aug 2022

United BioPharma gets FDA approval for phase 2 HIV drug trial

Taiwan-headquartered United BioPharma (UBP) says the U.S. Food and Drug Administration (FDA) has approved a phase 2 clinical trial IND submitted by the U.S. National Institute of Allergy and Infectious Diseases (NIAID) of NIH. The purpose of the study is to assess the safety and antiviral activity of UB-421 in combination with optimized background ART […]

August 31, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 31 Aug 2022

Emactuzumab designated as an orphan medicinal product for TGCT in Europe

SynOx Therapeutics Limited says its novel monoclonal antibody, emactuzumab, in development for the treatment of tenosynovial giant cell tumor (TGCT) and other diseases, has been designated as an orphan medicinal product for both localized and diffuse types of the disease by the European Medicines Agency (EMA). No systemic treatments have been approved for TGCT in […]

August 31, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 31 Aug 2022

Laverock Therapeutics created to develop next generation of programmable cell therapies

Laverock Therapeutics Ltd has been founded to develop a gene silencing platform for the creation of programmable, allogeneic cell therapies. Having recently completed a seed funding round, the U.K. company has opened dedicated labs in the Stevenage Bioscience Catalyst, employing six new team members on top of its senior management team. Laverock Therapeutics started out […]

August 31, 2022 - 2 minutesmins - By Jim Cornall

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Sanofi’s first treatment in the U.S. approved for adults and children with ASMD

Labiotech adds conference and event listings

Ensysce Biosciences and Quotient Sciences to develop opioid to prevent abuse and overdose

Gel treatment for erectile dysfunction receives positive results from clinical trial

Regulatory approval given to Iceland’s EpiEndo for study of COPD treatment

Anti-cancer drug created from reprogrammed yeast

Researchers try to bridge gap in link for patients with salmonella infection and clogged arteries

Compound found in trees has potential to kill drug-resistant bacteria

Researchers identify possible target for type of sporadic ALS

United BioPharma gets FDA approval for phase 2 HIV drug trial

Emactuzumab designated as an orphan medicinal product for TGCT in Europe

Laverock Therapeutics created to develop next generation of programmable cell therapies

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!